miltefosine has been researched along with 2019 Novel Coronavirus Disease in 2 studies
miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin
miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pillaiyar, T | 1 |
| Laufer, S | 1 |
| Soto, JA | 1 |
| Méndez, MI | 1 |
| Berman, JD | 1 |
1 review available for miltefosine and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Humans; Protein Kinase Inhibitors; SARS-CoV-2; | 2022 |
1 other study available for miltefosine and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Case Report: COVID-19 Misdiagnosed as a Drug Reaction to Miltefosine.
Topics: COVID-19; Diagnostic Errors; Humans; Male; Middle Aged; Phosphorylcholine; SARS-CoV-2; Young Adult | 2021 |